Controlled Substances - As enacted, authorizes additional healthcare providers to directly administer buprenorphine mono or buprenorphine without the use of naloxone; adds that prescribing a buprenorphine product to nurs, the official text

··••111

    •••••Q• ·t,---..-n;;-_i:E.;r

    ~
•   \l~j: .,1,

:   C~l,];URfi

!.  "1(;( d~:

           ·~·

~tate of \lrennessee

PUBLIC CHAPTER NO. 753

                          HOUSE BILL NO. 1984
By Representatives Hill, Grills, White, Tim Hicks, Crawford

                Substituted for: Senate Bill No. 1848

                                                    By Senator Massey

         AN ACT to amend Tennessee Code Annotated, Title 53, Chapter 11, relative to the use
of buprenorphine products.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF TENNESSEE:

         SECTION 1. Tennessee Code Annotated, Section 53-11-311(b)(1), is amended by
deleting subdivision (D) and substituting:

                             (D) Directly administered the buprenorphine mono or buprenorphine
                   without use of naloxone by a healthcare provider, acting within the healthcare
                   provider's scope of practice, for the treatment of substance use disorder pursuant
                   to a medical order or prescription order from a physician licensed under title 63,
                   chapter 6 or 9 or a healthcare provider identified in subdivision (c)(2). This
                   subdivision (b)(1)(D) does not permit buprenorphine mono or buprenorphine
                   without use of naloxone to be dispensed to a patient in a manner that would
                   permit it to be administered away from the premises on which it is dispensed.

         SECTION 2. Tennessee Code Annotated, Section 53-11-311(c)(2), is amended by
deleting subdivision (H) and substituting:

                   (H) Does not prescribe or dispense a mono product or buprenorphine without
         naloxone, except to a pregnant woman, nursing mother, a patient with a documented
         history of an adverse reaction or hypersensitivity, or when prescribing an injectable
         mono product;

         SECTION 3. This act takes effect upon becoming a law, the public welfare requiring it.
         HOUSE BILL NO. 1984

PASSED:  March 30. 2026

                             c:.'d:_L

                                           CAMERON SEXTON, SPEAKER
                                          HOUSE OF REPRESENTATIVES

                         R« ◄~' 1)'.R.A.N~D~YNALLY
                                                SPEAKER OF THE SENATE

APPROVED this no"'- day of Apt;\  2026

     ~lu.

BILL LEE, GOVERNOR